
|Videos|December 2, 2013
Novel PET Imaging in Prostate Cancer
Author(s)Evan Y. Yu, MD
Evan Y. Yu, MD, discusses the role of PET imaging in prostate cancer.
Advertisement
Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, Seattle Cancer Care Alliance, discusses the role of PET imaging in prostate cancer.
Clinical Pearls:
- Various types of PET imaging can be used to help detect prostate cancer and measure prostate cancer treatment responses
- A study that explored sodium fluoride PET as a marker in treatment response with dasatinib showed a longer progression-free survival
- PET imaging showed that ARN-509 was hitting its intended target and helped researchers determine the optimal biologic dosing for the agent
- Using PET imaging in clinical trials will help researchers get a better understanding the mechanism of action of some novel agents
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
2
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
3
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























